Biosim­i­lars unite: Look­ing for com­mer­cial con­sol­i­da­tion, Bio­con buys out long­time part­ner Vi­a­tris for $3.3B

Turn­ing a years-long part­ner­ship in­to own­er­ship, Bio­con is shelling out $3.335 bil­lion to buy out Vi­a­tris’ biosim­i­lars busi­ness.

Re­ports first emerged weeks ago about plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER